Abstract:Purpose We present the result of a comparison study between conventional chemotherapy and HCT for Peripheral T-cell lymphomas (PTCLs) in our center, especially the comparison between allo-HCT and auto-HCT. Patients and Methods From July 2007 to July 2014, 112 cases were analyzed retrospectively. All 112 patients were high risk group (IPI®3-4), 52 patients received conventional chemotherapy alone and 60 patients underwent HCT. In HCT group, Twenty-one (36.5%) patients received allo-HCT and thirty-nine patients (63.5%) received auto-HCT. Before receiving transplantation, 40 patients were in complete remission (CR), 2 patients were in partial remission (PR) and 18 patients were in refractory or relapse (NR). In the 18 NR patients, 11 patients accepted allo-HCT and 7 patients accepted auto-HCT. Patientsi¯ baseline characteristics were listed in Table 1 and Table 2. Results In this study, the longest follow-up time was 76 months and the shortest follow-up time was only two months. After chemotherapy, 31/52 patients achieved complete remission (CR)£¬5/52 patients achieved PR and 16/52 patients were not remission£i§NR). The overall response rate was 69.2%. However, 14 patients suffered relapse in 36 responding patients, the recurrence rate was close to 50%. In allo-HCT group, 19/21 patients achieved CR and 2/21 patients died of severe infection within 100 days after HCT. In auto-HCT patients, 35/39 patients achieved CR and 4/39 patients were in NR. 7 patients experienced relapse after auto-HCT. After a median follow-up of 33.5 months, the K-M analysis showed that the 5-year PFS for HCT and chemotherapy were 60% and 30% ( p =0.006), the 5-year OS were 65% and 33% ( p =0.007). The difference between the two groups was significant The 5-year PFS for auto-HCT and allo-HCT were 61% and 60% (p=0.724). The 5-year OS were 62% and 61% (p=0.724). In transplant group, the 5-year OS for patients who were CR or NR before transplantation were 81% and 53% (p=0.303). The one-year cumulative TRM of allo-HCT and auto-HCT were 22.5% and 7.8% (p=0.250). For patients whose ages are below 50, the 2-year PFS for HCT and chemotherapy were 62.7% and 34.8% ( p =0.017), the 3-year OS were 71.2% and 36.7% ( p =0.033). The one-year TRM of HCT and chemotherapy were 15.5% and 12.4% ( p =0.203). For patients more than 50 years old, the 1-year OS for HCT and chemotherapy were 85.7% and 66.5% ( p =0.384). And the one-year TRM of HCT and chemotherapy were 28.6% and 33.3% ( p =0.352). Conclusion The majorities of PTCL patients are at high risk and have a high recurrence rate after conventional chemotherapy alone. Our results suggest that HCT is superior to conventional chemotherapy in long-term survival for PTCLs and HCT is feasible for high-risk patients with low TRM, especially in the young patients. Therefore, HCT should be considered to be the first-line therapy in high risk PTCL patients. As to PFS and OS, there seems to be no difference between auto-HCT and allo-HCT. While before transplantation, there are more NR and relapsed patients in allo-HCT group, we recommend allo-HCT for refractory and relapsed patients. Disclosures No relevant conflicts of interest to declare.

[Clinical Outcomes of Peripheral Blood Stem Cell Transplantation for Aggressive Peripheral T-cell Lymphoma].

[Long Term Curative Effects and Prognostic Analysis of Stem Cell Transplantation for Treating Patients with Peripheral T Cell Lymphoma].

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Primary breast T-cell lymphoma, unspecified, treated with autologous peripheral blood stem cell transplantation: A case report and literature review.

Decreased peripheral blood lymphocyte-monocyte ratio and platelet-monocyte ratio and the Peripheral Blood Score model predict poor survival in peripheral T-cell lymphoma patients

[Evaluation of Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/refractory Peripheral T-cell Lymphoma with Chemoresistance].

Outcomes of Myeloablative Peripheral Blood Stem Cell Transplantation for Non-Complete Remission Patients with Relapsed/refractory Peripheral T Cell Lymphomas

A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China

Outcomes of autologous versus allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas: A multicenter retrospective study in china.

Autologous Hematopoietic Stem Cell Transplantation Improves Survival Outcomes in Peripheral T-cell Lymphomas: a Multicenter Retrospective Real-World Study

Frontline Allogeneic And Autologous Hematopoietic Cell Transplant For Peripheral T-Cell Lymphomas (Ptcls): A Comparison Study Between Conventional Chemotherapy And Hematopoietic Cell Transplant From A Chinese Center

Autologous Peripheral Blood Stem Cell Transplantation Is More Therapeutically Effective In The Patients With Hematologic And Solid Tumors.

[Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Hematologic Malignancies].

[Outcomes of 33 Patients with Anaplastic Large Cell Lymphoma Treated after Hematopoietic Stem Cell Transplantation].

Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]

Current Status of Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Peripheral T-cell Lymphoma

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis

Autologous Stem Cell Transplant for Refractory and Relapsed Peripheral T-cell Lymphoma: a Retrospective Study in China.

A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy

Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas